VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
about
Immune checkpoint blockade in infectious diseases.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.Trial watch: Immune checkpoint blockers for cancer therapy.Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations.Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.A drug development perspective on targeting tumor-associated myeloid cells.The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.Scientists Investigate the Application of Immunotherapy to Many Cancer Sites: Breast and prostate cancers prove more challenging, but progress is occurring.Checks and Balances in Autoimmune Vasculitis.Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.Next generation immune-checkpoints for cancer therapy.Alloreactive cytotoxic T lymphocyte immunotherapy treatment of a patient with metastatic prostate cancer: A case report.Not All Immune Checkpoints Are Created EqualImmuno-Oncology: Emerging Targets and Combination TherapiesMonitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular CarcinomaWhite paper on microbial anti-cancer therapy and preventionGenetics and biology of prostate cancerTIM-3 expression in breast cancerGenetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulationDynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular DiseaseThe Identification of Immunological Biomarkers in Kidney Cancers
P2860
Q41921732-511F82C2-9723-42A3-B028-A18A20087E98Q42369857-7CFFE1E3-74BF-48F9-8B30-9E77EBA709ADQ43578455-51FDFF09-694A-4FA4-8042-BCB9E1C6E652Q46112903-8D9A2F1B-8E92-4B80-94C5-F3C83B5E365AQ47139628-4EBC5449-1226-4C13-AD27-8D3861020B2DQ47332473-FCFE8EA0-08BA-4651-937F-98657AC936C4Q47393365-DA5EF042-9BC7-4D18-93EA-0B1DAD0CFBCBQ47557991-295F1FB2-7019-4393-9169-ECFA2D0A96BCQ47772214-1AAC4621-8ABA-468E-AF44-54ADD115F214Q48156081-F5F66C21-4FF6-4774-A82D-A935C7D1D7A7Q48652546-A51A1A3F-1814-4449-8A29-CDF45FE86063Q49545290-24077704-05C7-451E-A283-FEB95A15322FQ50061490-78B4DDB5-832E-415B-95C3-6FA120D904E4Q51764698-77870FE4-3BB8-4BCF-AC9A-2D3DEAA3AB0CQ52659572-25D7BDBB-6BE7-49BB-A7BF-6F7ADAFDA847Q52683991-F06EE1AA-834A-4F38-B418-2AB0F3E650CAQ54218762-C81E88BC-88C6-463E-9FF4-4E0E9DEA4AF8Q54960920-F64B68EE-A4CE-4218-8147-7768BEDAC751Q55020853-46132B3D-476E-4398-8D31-BEBAA568C2E2Q55114350-EBD6C11F-DD9C-41AA-8193-42AA8796DA10Q55383705-7D9803C6-0B13-4057-B40F-43E74857133FQ55403719-F8023D91-9DB6-4B3A-A5FC-E1C1A3EEA64CQ56889626-8567330E-F375-4492-909C-246808708871Q56889817-D70641CB-3EDD-4205-972B-8689DAC9FFFFQ56891008-51A730C4-CC3B-47C7-A122-B410D748EEA8Q56898750-A8D397E3-49D5-4160-9AB9-AAC0B11D0070Q57106917-39691A7F-9E4C-437B-B494-C693D5DD35C7Q58129671-4E88F8F9-430D-4F32-8AF6-295EE21FA5A5Q58759808-D78105D0-AAE0-478E-8FDD-86BAE172A02EQ58801536-2EC43DC4-C89B-4D67-8311-8590B3F5BF27Q59132089-425F6E06-7A0F-42B8-A45A-5652AE395E2A
P2860
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
VISTA is an inhibitory immune ...... patients with prostate cancer.
@en
type
label
VISTA is an inhibitory immune ...... patients with prostate cancer.
@en
prefLabel
VISTA is an inhibitory immune ...... patients with prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
VISTA is an inhibitory immune ...... patients with prostate cancer.
@en
P2093
Christopher J Logothetis
Curtis A Pettaway
Eleni Efstathiou
Jennifer Wargo
Jianfeng Chen
Jianjun Gao
Jingjing Sun
John F Ward
P2860
P2888
P304
P356
10.1038/NM.4308
P407
P577
2017-03-27T00:00:00Z